Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Adagene Inc (NASDAQ:ADAG) announced data from its presentation at the American Society of Clinical Oncology 2024 Gastrointestinal Cancers Symposium.
Results come from dose escalation and dose expansion cohorts of ADG126 in combination with Merck & Co Inc (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab) (200 mg/Q3W) evaluating doses from 6 mg/kg to 10 mg/kg in heavily pre-treated advanced/metastatic patients (N=46):
In a preliminary PFS analysis of those MSS CRC patients free of liver and peritoneal metastasis, a median PFS of seven months was observed in those treated with ADG126 10 mg/kg at two dosing frequencies pooled together [every three weeks (n=9) and every six weeks (n=6)].
The durable clinical activity of ADG126 in combination with pembrolizumab will continue to be evaluated as a larger cohort of subjects becomes evaluable at the 10 mg/kg Q3W dose level.
Price Action: ADAG shares are down 45.80% at $2.05 on the last check Wednesday.
Photo via Shutterstock